Heal Without builds the consumer-facing infrastructure that SofPulse has not yet built: patient discovery, LMN-gated purchasing, HSA/FSA payments, and surgeon slipstream enrollment. Your device. Our channel. Shared upside.
DTC patient acquisition (SofPulse current state)
Fully loaded cost per medical device rep per year
Revenue from surgeon relationship post-prescription
The Gap Analysis
Based on public-facing analysis of sofpulse.com, clinical publications, and distribution announcements. Each gap is a direct match to what Heal Without has already built.
Zero patient discovery
A patient Googling 'recover from knee surgery without opioids' finds nothing from SofPulse. healwithout.com owns that intent.
Direct-with-Rx pathway exists but has no UX
Your site acknowledges patients can order with a prescription — but there's no page, no checkout, no flow. We build that.
No patient education after prescription
Once the device is placed, you disappear from the patient journey. No onboarding, no adherence support, no re-order pathway.
Cosmetic surgery is under-commercialized
Your strongest RCT data (57% pain reduction, 2.2x narcotic reduction) is in plastic surgery. Cash-pay patients. No insurance friction. Zero DTC presence.
Rep model scales linearly, not exponentially
Each rep costs $254K/year fully loaded and ramps for 12-18 months. A digital channel scales algorithmically with no headcount.
No revenue from the surgeon relationship
When a surgeon prescribes your device, you earn one device sale. The slipstream model adds $105.55/patient/month in RTM revenue — captured by the surgeon's care team through our platform, sustained by your device.
The Slipstream Model
Heal Without inverts the traditional device sales model. Patients pull surgeons onto the platform — no rep required. This is the structural advantage of DTC over physician rep channels.
Via Google, arthritisrisk.com, or condition-site referral. Already pre-qualified by pain/recovery intent.
Sage AI drafts the Letter of Medical Necessity. Our medical director — a 50-state-licensed physician — reviews and signs in ~3 minutes. Patient pays $199 — HSA/FSA eligible.
Purchases the tPEMF device ($1,900) with HSA/FSA card — zero out-of-pocket friction. Device ships directly from SofPulse fulfillment.
Within 24 hours, patient's surgeon receives: 'Your patient purchased SofPulse tPEMF post-op. One click to enroll in RTM monitoring.' No sales call. No rep required.
Surgeon clicks to enroll in Remote Therapeutic Monitoring. CMS pays 98975 (setup) + 98977 (device supply) + 98980 (treatment management) = $127.26 first month, $105.55/month ongoing per active patient. Reimbursed under the clinician's own NPI for the documented patient-data review these codes require.
Net result for SofPulse
Each patient purchase triggers automatic surgeon notification + RTM enrollment. Surgeon care teams are reimbursed $105.55/month under their own NPI for the documented RTM monitoring these codes require — so the device fits into ongoing post-op care, not just a one-time sale. Patient purchases become a physician acquisition engine.
Channel Economics
These are not mutually exclusive. Heal Without runs parallel to your physician channel — and creates pull that makes reps more productive.
| Metric | Physician rep channel | Heal Without DTC |
|---|---|---|
| Cost per acquisition | $254K/yr per rep ÷ 60 units | $150–300 digital CAC |
| Ramp time | 12–18 months | 2–4 weeks |
| Scale path | Linear (hire more reps) | Algorithmic (Meta/Google/SEO) |
| Effective margin after channel cost | 27–32% | 55–63% |
| Patient education & adherence | None after dispense | Protocol + recovery content |
| Surgeon notification | Manual, if at all | Automatic within 24 hours |
| RTM revenue for surgeon | Not offered | $105.55/patient/month |
| HSA/FSA friction | Patient pays OOP | LMN via telehealth = zero friction |
Priority Verticals
The cosmetic surgery vertical is the recommended pilot: strongest published RCT, cash-pay patients, no insurance friction, high willingness to pay for recovery optimization. OEM-equivalent for DTC tPEMF.
57% VAS pain reduction, 2.2× narcotic reduction
Source: Rohde et al., Plast Reconstr Surg
Cash-pay, brand-conscious, no insurance friction
Significant opioid reduction (NELA trial, 2023)
Source: Peer-reviewed, orthopedic focus
High volume, Medicare/commercial, 800K/yr in US
Pain/edema reduction, same mechanism as TKA
Source: FDA 510(k) clearance scope
Adjacent to TKA — same patient, same surgeon
Post-surgical pain & edema reduction, soft-tissue mechanism
Source: FDA 510(k) post-surgical clearance
Sternotomy recovery — a high opioid-burden surgery
What We Bring
Heal Without is not a proposal. It is a deployed system. These components are live today.
SEO + Meta + condition sites (arthritisrisk.com, 1M+ impressions/month). Patient arrives pre-qualified by recovery intent.
Sage AI generates Letters of Medical Necessity. A 50-state-licensed physician reviews and signs in ~3 minutes. Device purchase becomes HSA/FSA eligible.
Sage AI drafts the Letter of Medical Necessity. Licensed physician reviews and signs in under 24 hours. Patient pays with pre-tax HSA/FSA dollars. Zero-friction purchase flow.
Automatic 24-hour notification to patient's surgeon. One-click RTM enrollment earns $105.55/month from CMS — built into SurgeonValue platform.
Two-sided physician attestation marketplace. Every LMN = cryptographic audit trail. WORM-anchored hash. OIG defensible.
Post-surgical recovery library, condition-specific protocols, adherence nudges. Patient education that drives outcomes and repeat trust.
Proposed Structure
We're flexible. The goal is to start fast, prove volume in one surgical vertical, and expand from there.
Heal Without earns a margin on each SofPulse device sold through our channel. Typical DTC distribution margin: 20–30%. SofPulse retains full physician channel.
SofPulse provides preferred wholesale pricing ($500–600/unit). Heal Without drives volume, owns the DTC relationship. Best margin for both sides at scale.
Heal Without brands the device under the HealWithout product line. SofPulse manufactures. Separate SKU from physician channel — no channel conflict.
Revenue Model
Based on digital CAC benchmarks for medical device DTC and current arthritisrisk.com warm audience. Excludes RTM, LMN, and ClinicalSwipe revenues.
| Period | Monthly units | Annual units | Gross revenue | Channel margin (63%) |
|---|---|---|---|---|
| Year 1 (H2 ramp) | 10 | 60 | $114K | $72K |
| Year 2 | 50 | 600 | $1.14M | $719K |
| Year 3 | 200 | 2400 | $4.56M | $2.87M |
Assumes $1,900 retail ASP, $650 wholesale (base scenario), $150–300 CAC. RTM adds ~$88/patient/month to surgeon economics — increases physician pull and repeat prescription rate.
Cosmetic/plastic surgery is the recommended pilot: your strongest RCT, cash-pay patients, no insurance gatekeeping. Prove 50 units in 6 months. Then expand.
healwithout.com
Live DTC site — built, deployed, indexed
Physician-reviewed platform
FDA-cleared tPEMF · HSA/FSA eligible · RTM-billed
Contact our team
hello@healwithout.com